12.00
-0.75(-5.88%)
Currency In USD
| Previous Close | 12.75 |
| Open | 12.9 |
| Day High | 12.9 |
| Day Low | 12 |
| 52-Week High | 76 |
| 52-Week Low | 4.56 |
| Volume | 22,973 |
| Average Volume | 35,087 |
| Market Cap | 54.26M |
| PE | -4.29 |
| EPS | -2.8 |
| Moving Average 50 Days | 14.25 |
| Moving Average 200 Days | 11.67 |
| Change | -0.75 |
If you invested $1000 in MiNK Therapeutics, Inc. (INKT) since IPO date, it would be worth $100 as of November 18, 2025 at a share price of $12. Whereas If you bought $1000 worth of MiNK Therapeutics, Inc. (INKT) shares 3 years ago, it would be worth $451.13 as of November 18, 2025 at a share price of $12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
GlobeNewswire Inc.
Nov 14, 2025 12:30 PM GMT
New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive funding from NIH- and philanthropic grantsLaunching Ph
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune remodeling underscore agenT-797’s potential to
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
GlobeNewswire Inc.
Nov 05, 2025 2:07 PM GMT
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announ